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Introduction: Several new medications are now available for immunosuppression in the 
kidney transplant field. Tacrolimus and mycophenolate mofetil were first introduced for 
  immunosuppression in renal transplantation in the mid 1990s. Since then, the combination 
of tacrolimus and mycophenolate mofetil has been evaluated in numerous clinical trials. The 
outcomes of these trials have varied due to differences in induction and/or maintenance therapy, 
drug dosing and monitoring protocols, and study design. The aim of this review is to analyze 
the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil 
combination therapy in renal transplantation.
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Introduction
With the introduction and availability of several immunosuppressive drugs with differ-
ent mechanisms of action, kidney transplantation has become the treatment of choice 
in end-stage renal disease. Immunosuppressive drugs are given to kidney transplant 
recipients in two phases, ie, induction and maintenance. The induction phase usually 
includes short courses of various antibodies against T lymphocytes, along with high 
doses of steroids. Four classes of drugs are available for maintenance immunosup-
pression, ie, corticosteroids, antimetabolites (azathioprine [AZA] and mycophenolate 
mofetil [MMF]/mycophenolate sodium), calcineurin inhibitors (cyclosporine [CSA] 
and tacrolimus [TAC]), and target of rapamycin inhibitors (sirolimus [SRL] and 
everolimus). The aim of maintenance immunosuppression is to avoid acute rejection, 
interstitial fibrosis and tubular atrophy (IFTA), and to improve overall graft and patient 
survival. Conventional immunosuppression regimens consist of various combinations 
of two or three agents from different groups. These drugs act on different phases of 
the cell cycle to inhibit either activation or proliferation of T lymphocytes (Figure 1), 
which are the major mediators of acute cellular rejection. Most of the aforementioned 
agents have several serious side effects which are usually related to dose and duration 
of treatment. The rationale for combining medications from different classes is to 
achieve adequate immunosuppression while limiting side effects. Different transplant 
centers in the US use different combinations of immunosuppressive medications 
during the maintenance phase, and no optimal immunosuppressive strategy has been 
determined as yet.
In this review article, we discuss the pharmacology and pharmacokinetics of MMF and 
TAC, their efficacy as maintenance immunosuppressive treatment in renal   transplantation International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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compared with other commonly used   immunosuppressive drug 
combinations, and their side effects.
Pharmacology of tacrolimus
TAC binds to an immunophilin, ie, FK binding protein. 
The complex of TAC–FK binding protein inhibits the phos-
phatase activity of calcineurin. The calcineurin enzyme is 
responsible for the dephosphorylation reactions required 
for early lymphokine gene transcription. Inhibition of 
calcineurin phosphatase prevents transcription activation 
of T cells, mainly via interleukin (IL)-2 and prevents the 
progression of T cells from the G0 to G1 phase. This results 
in inhibition of T cell proliferation in response to antigens 
and also generation of cytotoxic T cells. On a weight basis, 
TAC is 10–100 times more potent then CSA in inhibiting 
T cell proliferation.1,2
Pharmacokinetics of tacrolimus
After oral administration, TAC reaches peak plasma con-
centration in 30 minutes to one hour.3 The bioavailability 
of TAC is variable, ranging from 5%–93%, with a mean 
of 25%.4 Poor water solubility of TAC and reduced gut 
motility in transplant recipients is responsible for the low 
absorption of TAC. Reduced bioavailability is reported in 
African-Americans, diabetics, and patients waiting for renal 
transplantation.5–12 Administration with food containing 
a moderate amount of fat can also reduce absorption and 
bioavailability.13,14
After absorption, TAC binds to both erythrocytes and 
plasma proteins. Erythrocytes bind to 75%–80% of the 
drug. Of the remaining 20%–25% of TAC in plasma, 99% 
binds to plasma proteins, mainly to albumin and alpha-1 
acid glycoprotein. The distribution of TAC between 
plasma and erythrocytes is dependent on hematocrit, TAC 
concentration, and temperature. The blood concentration 
of TAC is about 15 times higher than the corresponding 
plasma concentration. Less than 0.1% of the unbound 
fraction of the drug is responsible for its pharmacologic 
activity. Measurement of blood/plasma concentration 
of TAC consists of both bound and unbound fractions 
of the drug. These are useful surrogate markers of the 
active drug level.15,16 TAC crosses the placenta and is also 
excreted in breast milk. Presystemic metabolism of TAC 
occurs in the intestinal mucosa by cytochrome P450 (CYP) 
3A4 isoenzymes and P-glycoprotein. In the liver, TAC is 
extensively metabolized by the CYP 3A4 and CYP 3A5 
isoenzymes.   Polymorphisms, or genetic variations, of these 
isoenzymes are known to affect the dosage requirement 
and trough levels of TAC in stable transplant patients.17 
Drugs   causing either inhibition or induction of the CYP 
3A system may increase or decrease serum concentra-
tions of TAC. Corticosteroids induce both CYP 3A and 
P-glycoprotein activity and, therefore, a higher dosage of 
TAC is required to achieve target trough levels when used 
in combination with corticosteroids.18 TAC metabolites are 
mainly excreted via the biliary route. Less than 1% of TAC 
is excreted unchanged in urine and stool.
Monitoring of TAC levels is important for both safety 
and efficacy in transplant recipients. The lower values of the 
tacrolimus area under the blood concentration-time curve 
(AUC ,200 ng/hr/mL) on the second post-transplant day 
has been shown to be associated with a higher risk of acute 
rejection.16 A good correlation exists between the AUC and 
TAC concentration 12 hours postdose (trough level).19 The 
AUC value of 200 ng/hr/mL correlates with a TAC trough 
level of 10 ng/mL.20 Trough levels .15 ng/mL have been 
associated with significant toxicity but without a signifi-
cant reduction in acute allograft rejection.21 In the recently 
performed ELITE (Efficacy Limiting Toxicity Elimination) 
Symphony trial, a low trough level of TAC (3–7 ng/mL) was 
compared with low and standard doses of CSA and SRL in a 
quadruple regimen including daclizumab, MMF, and steroids. 
The low-dose TAC group had the lowest acute rejection rate 
with the highest glomerular filtration rate (GFR) at 12 months 
post-transplantation.22
Pharmacology of mycophenolate 
mofetil
MMF is an ester prodrug of mycophenolic acid (MPA). 
Two major pathways are involved in purine synthe-
sis, ie, the de novo pathway and the salvage pathway. 
MPA inhibits inosine-5’-monophosphate dehydrogenase 
(IMPDH), the rate-limiting enzyme in the de novo pathway 
of purine synthesis. Therefore, it prevents the formation 
of guanosine monophosphate, guanine triphosphate, and 
deoxyguanine triphosphate, and ultimately inhibits DNA 
generation and cell replication. MPA is five times more 
potent as an inhibitor of the Type II isoform of IMPDH, 
which is expressed in activated T and B lymphocytes, 
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than of the Type I isoform, which is expressed in most cell 
types.23 Due to the expression of the more susceptible form 
of IMPDH, MPA preferentially inhibits de novo guanosine 
nucleotide synthesis in lymphocytes. By preferential deple-
tion of guanosine and deoxyguanosine nucleotides in T and 
B lymphocytes, MPA suppresses both cell-mediated immune 
responses and antibody formation, which are major factors 
in both acute and chronic allograft rejection.
In addition to inhibition of DNA synthesis in   lymphocytes, 
depletion of guanosine nucleotides suppresses the   expression 
of several adhesion receptors, including vascular cell   adhesion 
molecule 1, E-selectin, and P-selectin, on vascular endothelial 
cells.24 This interferes with the attachment of leukocytes to 
endothelial cells and prevents the recruitment of lymphocytes 
and monocytes to sites of inflammation.25,26 Suppression of 
mononuclear cell recruitment is another mechanism by which 
MMF decreases acute and chronic graft rejection. Activation of 
inducible nitric oxide synthase is correlated with renal allograft 
rejection. Suppression of inducible nitric oxide synthase 
activity and nitric oxide production is presumably one of the 
mechanisms by which MMF prevents allograft rejection.27
Pharmacokinetics  
of mycophenolate mofetil
Following oral administration, MMF is absorbed rapidly and 
completely. It undergoes hepatic de-esterification to form 
MPA, an active immunosuppressant. The bioavailability of 
MPA from MMF is about 94%, and reaches peak plasma 
concentration about two hours after oral administration.28 
MPA undergoes hepatic glucuronidation to form mycophe-
nolic acid glucuronide (MPAG), which is pharmacologically 
inactive. MPAG is secreted into the bile and is converted 
back to MPA by gut bacteria. MPA is then reabsorbed and, 
via hepatic recirculation, produces a second peak at 8–12 
hours.28 MMF is excreted in the urine as MPAG, account-
ing for 90% of the administered MMF dose.29 Renal failure 
or hemodialysis has no effect on plasma concentration of 
free MPA, and no dosage adjustment is required for such 
patients.30,31
Pharmacokinetics of mycophenolate 
mofetil–tacrolimus in combination
MMF and TAC are frequently used in combination as a main-
tenance immunosuppressive regimen in kidney transplant 
recipients. The rate of absorption and systemic bioavail-
ability of TAC remains unchanged in the presence of MMF. 
Therefore, no adjustment in dosing is required when TAC is 
coadministered with MMF.32
Concomitant administration of MMF with calcineurin 
inhibitors affects the pharmacokinetics of MPA. CSA inhibits 
the enterohepatic recirculation of MPAG while TAC does not 
interfere with it. Therefore, the second peak in the MPA level 
is more pronounced in patients receiving TAC.33,34 Higher 
levels of MPA trough levels and AUC were observed when 
MMF is used in combination with TAC compared with its use 
in combination with CSA.35 These suggest that lower doses of 
MMF are required to achieve adequate immunosuppression 
when used with TAC, compared with CSA.
Mycophenolate mofetil–tacrolimus 
for maintenance immunosuppression
TAC was first discovered in 1984 as a macrolide immuno-
suppressant and approved by the US Food and Drug Admin-
istration in 1994 for use in organ transplantation.36 Since 
then, TAC has been used in different combinations in renal 
transplant recipients. In this review, we discuss important 
studies done in the field of adult kidney transplantation 
where the TAC–MMF combination was used as maintenance 
immunosuppression with or without steroids. Because clini-
cal trials are not always designed to compare TAC–MMF 
with other immunosuppressive combinations, a head-to-head 
comparison of study outcomes is not possible.
Tacrolimus–prednisone with and 
without mycophenolate mofetil
Initial studies compared the efficacy of TAC–prednisone 
with TAC–prednisone–MMF combinations in reducing 
the incidence of acute rejections. More than 200 patients 
undergoing kidney transplantation were randomized 
to receive either TAC–prednisone (TAC–P, n = 106) or 
TAC–prednisone–MMF (TAC– P -MMF, n = 102) between 
September 1995 and September 1997. Mean follow-up was 
15 ± 7 months. The rate of acute rejection was higher in the 
TAC–P group compared with the TAC–P–MMF group (44% 
versus 27%, P = 0.014). Overall patient and graft survival 
were similar in both groups.37 In another randomized study, 
the rate of acute rejection was lower at six months in the 
low-dose TAC–P–MMF 1 g or 2 g groups compared with a 
TAC–P group. Higher doses of MMF were associated with 
more toxicity without an improvement in efficacy.38 These 
studies showed that adding MMF to TAC–P reduced acute 
rejections and improved overall graft and patient survival.
Recently, studies have attempted to avoid or withdraw 
steroids early from the immunosuppressive regimen. 
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study done by Woodle et al compared the outcomes of early 
steroid withdrawal (day 7 post-transplant) and chronic ste-
roid maintenance treatment using antibody induction and 
TAC–MMF maintenance therapy. At the end of five years, 
allograft survival and function were similar in both groups. 
Although the incidence of new-onset diabetes after transplant 
was similar, fewer patients in the steroid withdrawal group 
required insulin treatment.39 In a single-center,   retrospective 
sequential analysis of 212 renal transplant recipients with 
a median follow-up of five years by Gallon et al, there 
was no significant difference between rate and severity of 
acute   rejection episodes, graft survival, patient survival, 
and decline of renal function between the chronic steroid 
maintenance group (n = 96) and the rapid steroid elimination 
group (n = 116). All patients also received induction with 
an IL-2 receptor antagonist and maintenance immunosup-
pression with TAC–MMF. Patients in the chronic steroid 
group had a higher incidence of hyperlipidemia and post-
transplantation diabetes compared with the rapid steroid 
elimination group.40
Tacrolimus–mycophenolate mofetil 
versus cyclosporine–mycophenolate 
mofetil
MMF has been combined with either CSA or TAC with 
and without steroids for maintenance immunosuppression. 
Silva et al compared the safety and efficacy of a once-daily, 
extended-release TAC formulation with a twice-daily TAC 
formulation and CSA microemulsion. All patients received 
basiliximab induction, and concomitant MMF and steroid 
maintenance therapy. At one year, patient and graft survival 
was similar in all three groups and the TAC extended-release 
formulation was not inferior to twice-daily TAC dosing and 
CSA microemulsion in terms of biopsy-proven acute rejec-
tion, death, and graft loss.41
A retrospective analysis of the US Renal Data System 
containing data for 31,012 subjects was done comparing 
graft and recipient survival. Patients received their transplants 
between 01 January 1995 and 31 December 1999, with 
follow-up through to 31 December 2000. Three immunosup-
pressive regimens were analyzed, ie, prednisone–CSA–MMF 
(PCM, n = 17,108), prednisone–TAC–MMF (PTM, n = 7225) 
and prednisone–CSA–AZA (PCA, n = 6679). The risk of 
allograft failure was higher in the PTM (hazard ratio [HR] 
1.09, P , 0.05) and PCA groups (HR 1.15, P , 0.001) com-
pared with the PCM group. Similar associations were also 
demonstrated in the subgroup analysis comparing transplant 
periods before and after 1997 in living donor transplants 
in adult and kidney-only recipients.42 Patient survival was 
similar in all three groups.
In another retrospective analysis comparing TAC 
(n = 2393) and CSA microemulsion (n = 4686) with MMF 
and steroids in living donor renal transplantation, the adjusted 
risk for graft failure at two years was significantly higher in 
the TAC–MMF group compared with the CSA–MMF group 
(HR 1.25, P = 0.013).43
In a prospective trial by Johnson et al, recipients of a first 
cadaveric renal allograft were randomly assigned to receive 
TAC–MMF, CSA–MMF, or TAC–AZA as immunosuppres-
sive treatment. All patients received corticosteroids, but 
  antibody induction was given only to the patients experienc-
ing delayed graft function. All three groups had similar acute 
rejection rates and patient and graft survival at one year, but 
the incidence of steroid-resistant rejection requiring antithy-
mocyte antibody was lowest in the TAC–MMF group. Post-
transplant diabetes requiring insulin occurred in 14% of the 
TAC–AZA group, in 7% of the CSA–MMF group, and in 7% 
of the TAC–MMF group.44 At two- and three-year follow-up, 
all three regimens demonstrated excellent safety and efficacy. 
Patients treated with TAC–MMF who experienced delayed 
graft function had better two- and three-year allograft survival 
compared with patients receiving CSA–MMF (84.1% versus 
49.9%, P = 0.02 at three years). Patients receiving TAC with 
either MMF or AZA exhibited superior kidney function when 
compared with CSA.45,46
In the ELITE Symphony study, 1645 renal transplant 
recipients were randomized to receive one of four immuno-
suppressive regimens, ie, standard dose CSA, corticosteroids, 
and MMF, or daclizumab induction, MMF, and corticoster-
oids in combination with low-dose CSA, low-dose TAC, or 
low-dose SRL. The target trough levels for the low-dose CSA, 
low-dose TAC, and low-dose SRL groups were 50–100 ng/
mL, 3–7 ng/mL, and 4–8 ng/mL, respectively. At one year, 
the low-dose TAC–MMF group had the highest allograft 
survival rates (94% versus 89%–93%), highest GFR (65 mL/
min versus 57–60 mL/min), and lowest allograft rejection 
rates (12% versus 24%–37%).22
A recent meta-analysis and metaregression compared the 
positive and negative effects of TAC versus CSA as primary 
immunosuppression in kidney transplant recipients. Data 
from 30 trials including 4120 patients were included in the 
analysis. At six months, graft loss was significantly lower in 
the TAC group (relative risk 0.56, 95% confidence interval 
0.36–0.86) and this effect persisted for up to three years. At 
one year, TAC-treated patients had fewer acute rejections and 
fewer steroid-resistant rejections, but more diabetes requiring International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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insulin therapy. Rates of infections and malignancy were 
similar with both drugs.47
Tacrolimus–mycophenolate mofetil 
versus sirolimus–mycophenolate 
mofetil
Srinivas et al analyzed data for solitary kidney transplant 
recipients reported to the Scientific Registry of Renal 
T  ransplant Recipients during 2000–2005 to compare the out-
comes of different immunosuppressive regimens. The com-
bination of MMF–SRL was associated with a higher risk of 
acute rejection at six months post-transplantation compared 
with MMF–TAC (P , 0.01). Kaplan-Meier analysis showed 
inferior overall graft and patient survival with MMF-SRL 
compared with MMF–TAC and MMF–CSA at three years 
post-transplantation.48
In a randomized study comparing MMF–SRL–steroids 
with MMF–TAC–steroids, Larson et al did not find any dif-
ference in renal function at 12 months post-transplantation. 
The incidence of acute rejection was 10% in the TAC group 
and 13% in the SRL group (P = 0.58). Patient survival and 
graft survival were also comparable in both groups.49
Tacrolimus–mycophenolate versus 
tacrolimus–azathioprine
In a retrospective analysis, Schold and Kaplan compared the 
outcomes of TAC–MMF with TAC–AZA regimens in adult 
solitary kidney transplant recipients from 1998 to 2006. 
Overall graft loss was higher in patients treated with AZA. 
However, patients who received thymoglobulin induction 
or who were treated with the TAC–AZA combination had 
similar outcomes to those treated with TAC–MMF. There 
was no significant difference in development of malignan-
cies, renal function, or BK virus at one year. The study was 
limited by its retrospective nature and the significant inequal-
ity between the number of patients in the two groups (MMF 
group n = 94,747 and AZA group n = 3833).50
Tacrolimus–mycophenolate mofetil 
versus tacrolimus–sirolimus
Gralla and Wiseman analyzed data for 518 primary kidney 
transplant recipients at the University of Colorado Transplant 
Program during 2000–2006. Graft and patient survival, 
acute rejection episodes, and one-year GFR were compared 
between the TAC–MMF (n = 211) and TAC–SRL (n = 307) 
groups. Both groups received prednisone as part of the immu-
nosuppressive regimen. The authors analyzed and compared 
outcomes for two eras of transplant, ie, 2000–2002 versus 
2003–2006. One hundred and eighteen patients received 
TAC–SRL during 2000–2002 while 189 patients received 
TAC–SRL during 2003–2006. TAC–MMF was prescribed as 
immunosuppression to 54 and 157 patients during 2000–2002 
and 2003–2006, respectively. Although induction, prednisone 
taper, and antimicrobial prophylaxis were similar in both 
eras, a higher proportion of patients in the TAC–MMF group 
received induction therapy. The TAC–SRL 2000–2002 group 
had significantly lower three-year graft and patient survival 
compared with the TAC–SRL 2003–2006 group and both 
TAC–MMF groups. A higher incidence of cardiovascular 
death was responsible for lower patient and graft survivals 
in the TAC–SRL 2000–2002 group, which improved during 
the 2003–2006 period, most likely as a result of aggressive 
pretransplant screening and treatment of asymptomatic coro-
nary artery disease. Rates of acute rejection and BK virus 
nephropathy were similar, but anemia, hyperlipidemia, and 
new-onset diabetes were also more common at one year in 
the TAC–SRL group compared with the TAC–MMF group. 
One-year GFR was significantly lower in the TAC–SRL 
group compared with TAC–MMF (57.6 versus 63.1 mL/min, 
P = 0.008) during the 2003–2006 period. The results of this 
study are important, but there are some limitations as well, 
including its retrospective nature and lack of randomization 
between the SRL and MMF groups, leading to a disparity in 
the number of patients within each group.51
In a prospective, randomized, open-label study, Gallon 
et al compared TAC–MMF (n = 45) versus TAC–SRL (n = 37) 
in a prednisone-free maintenance immunosuppression regi-
men. All patients received basiliximab and methylprednisone 
as induction therapy. At three-year follow-up, graft survival 
and graft function were significantly better in the TAC–MMF 
group compared with the TAC–SRL group. There was no 
difference in the rate of anemia, new-onset diabetes, and 
cytomegalovirus (CMV) infection between the groups.52
Safety and tolerability
The safety and tolerability of MMF was established by three 
pivotal studies done by the US, European, and Tricontinental 
renal transplant MMF study groups. MMF was generally well 
tolerated in most studies. While the frequency of nausea was 
similar, the incidences of vomiting, diarrhea, and abdominal 
pain were higher in patients receiving MMF compared with 
those receiving AZA. Most symptoms resolved with dose 
reduction, or interruption or withdrawal of MMF.53–55 The 
invasive CMV infection rate was also higher in patients 
treated with MMF compared with those treated with AZA in International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
112
Dalal et al
initial studies. This increased incidence was possibly related 
to higher endoscopic surveillance as a part of the work-up 
for gastrointestinal symptoms and the absence of standards 
for CMV prophylaxis.53–55
Although a higher dose of MMF (3 g/day) was   associated 
with higher leukopenia at one year post-transplantation, 
there was no difference reported in the incidence of anemia, 
leukopenia, and thrombocytopenia between MMF 2 g/day 
and AZA at one year post-transplantation. The overall inci-
dence of skin malignancy was similar for MMF 3 g/day and 
AZA groups at three years post-transplantation. There was 
no statistically significant difference in the incidence of skin 
malignancy between MMF 2 g/day and AZA, at one year 
and three years after transplantation.56
Long-term studies in renal transplant patients have sug-
gested that CSA and TAC are equally nephrotoxic.57 The 
nephrotoxicity of calcineurin inhibitors is divided into acute 
and chronic groups. Acute oliguric tubular necrosis is a well-
known side effect of calcineurin inhibitors. This is usually 
caused by vasoconstriction of afferent and efferent arterioles, 
reduction in blood flow, and GFR.58 This acute side effect is 
dose-dependent, and renal function improves with cessation of 
therapy.59 TAC can also cause hyperkalemia, hyperuricemia, 
and, rarely, hemolytic uremic syndrome.60–63 Long-term use of 
calcineurin inhibitors is associated with IFTA. The pathologic 
features of IFTA include hyaline arteriolopathy, focal or striped 
tubulointerstitial fibrosis, and focal collapsing glomerulosclero-
sis.64 The chronic toxicity related to calcineurin inhibitor use is 
irreversible and affects long-term allograft survival.64
Some differences exist for the nonrenal side effects of CSA 
and TAC. Hypertension, dyslipidemia, and gingival hyperpla-
sia are most frequently reported with CSA. The occurrence of 
post-transplant diabetes is higher in patients receiving TAC. 
Inhibition of transcription of the gene for insulin by TAC is 
responsible for reduced insulin secretion and occurrence of 
post-transplant diabetes.65,66 High TAC trough concentra-
tions and concomitant use of steroids increase the risk of 
post-transplant diabetes.67 While diarrhea, vomiting, tremors, 
alopecia, and headache are more common with the use of TAC, 
constipation and cosmetic side effects including hirsutism, are 
more common with CSA.47,68 Hypertrophic cardiomyopathy is 
also reported in pediatric transplant patients on TAC.69,70
Conclusion
Maintenance immunosuppression is necessary for all 
patients receiving renal transplantation, except for the 
rare case of identical twins. From the 1960s to the early 
1980s, a combination of steroids and AZA was used to 
avoid allograft rejection in kidney transplant recipients.71 
Introduction of CSA in the late 1980s showed better 
allograft survival.71–73 Subsequent addition of MMF, TAC, 
and SRL has allowed large numbers of combinations as 
maintenance immunosuppression. Combining two or 
three drugs from different groups is universally used to 
achieve adequate   immunosuppression and to avoid adverse 
effects. In the initial studies, MMF was superior to AZA 
in reducing acute allograft rejection episodes at one year 
post-transplantation.53–55 Long-term follow-up of prospec-
tive studies and retrospective analysis of US registry data 
suggested reduction in late acute rejection episodes as 
well as reduction in IFTA independent of acute rejection 
episodes with MMF compared with AZA.74–77 Most of 
these studies were done before 2000 and used the old for-
mulation of CSA. A recent study done by Remuzzi using 
the microemulsion preparation of CSA did not find any 
difference in the rate of acute rejection, late rejection, graft 
loss, and GFR between the MMF and AZA groups with or 
without steroids. The cost of MMF therapy was 15 times 
higher than that of AZA therapy.78,79 Also, a retrospective 
analysis by Kaplan et al suggests similar outcomes with 
MMF and AZA when used in combination with TAC or 
with appropriate induction therapy.50 The low-dose TAC-
MMF combination had excellent overall allograft survival 
and better preservation of GFR, and with the lowest acute 
rejection rate compared with all other regimens in the 
ELITE Symphony trial.22 SRL in combination with a cal-
cineurin inhibitor as a primary immunosuppressive treat-
ment is usually associated with increased risk of graft loss 
and rapid decline in GFR.80 The SRL–MMF combination 
also has an overall higher risk of acute allograft rejection 
compared with TAC–MMF.48 These suggest that patients 
treated with SRL initially, in combination with any other 
medication, had an overall poor outcome. CSA and TAC 
are usually equally effective in combination with MMF 
as immunosuppressive treatment, but with differences in 
the side effect profile. Due to the chronic nephrotoxicity 
associated with calcineurin inhibitors, recent studies are 
attempting to replace calcineurin inhibitors with SRL 
several months post-transplantation. The data from the 
CONCEPT and Spare The Nephron studies have shown 
that patients switching from the MMF–calcineurin inhibi-
tor combination to MMF–SRL post-transplantation appear 
to have improved renal function compared with those who 
continue a calcineurin inhibitor-based regimen, without 
an increase in acute rejection rates.81 In the unpublished 
data of an ongoing prospective study at Northwestern International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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University, we have also found an improvement in GFR, 
without an increase in acute rejection rates on conversion 
of patients to SRL–MMF from TAC–MMF at 6–24 months 
post-transplantation.
In conclusion, TAC–MMF is a preferred maintenance 
immunosuppressive combination in adult renal transplant 
recipients. AZA can be used in place of MMF to reduce 
the cost of treatment. Switching patients from a calcineurin 
inhibitor to SRL several months post-transplantation appears 
to be an emerging option to reduce IFTA.
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